Inscripta Inc. (now Manus Bio Inc.)
The University of Colorado Connection
Groundbreaking CRISPR gene editing technology developed in the laboratory of Ìý(frm. CU °Ç¸ç³Ô¹Ï Chemical and Biological Engineering) led to the formation of genome engineering company Muse Biotech in 2015.Ìý Muse later became Inscripta,Ìýwhich raised over $400 million in venture capital funding.Ìý
Inscripta merged with Manus Bio in 2025 to create a leading company in industrial biotechnology.
Funding Status and Investment Opportunities
- Industry Applications: Biotech, Genomics, Manufacturing
- Funding Round: Acquired by Manus Bio Inc.
- Contact for Investment Inquiries:Ìý
In the News
- Manus and Inscripta merge to create a leader in industrial biomanufacturing (2025)
- Inscripta is reimagining what the synthetic biology company of the future will be (2023)
- The world's first fully automated benchtop digital genome engineering platform from CU spinout Inscripta is here (2021)
- Inscripta wins Company of the Year at Colorado BioScience Association's Annual Awards Celebration (2020)
- (2019)
ÌýÌý ÌýThis page was last updated on Sept. 8, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor eNewsletter
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at CU °Ç¸ç³Ô¹Ï.
For media inquiries, please visit .